抗击败血症引起的心肌功能障碍:新出现的机制和免疫调节突破
Can Liu1,2, Hanfeng Liu1,2, Yunxing Li1,2
1Department of Cardiovascular Surgery, The Affiliated Hospital, Southwest Medical University, Metabolic Vascular Diseases Key Laboratory of Sichuan Province, Key Laboratory of Cardiovascular Remodeling and Dysfunction, Luzhou, Sichuan, China.
Frontiers in immunology
|November 19, 2025
概括
败血症引起的心肌功能障碍涉及复杂的炎症,氧化应激和自主性问题. 新兴研究强调RNA甲基化和细胞外囊泡是关键参与者,为精密疗法铺平了道路.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 败血症引起的心肌功能障碍 (SIMD) 是死亡的主要原因.
- 机制包括炎症,氧化应激,自主功能障碍,以及像m6ARNA甲基化这样的新兴途径.
- 细胞外囊泡 (EVs) 在伤害传播和治疗中具有双重作用.
研究的目的:
- 审查SIMD背后的多方面的机制.
- 探索针对SIMD的新兴治疗策略.
- 为了将机械学的见解与精密疗法的临床创新相结合.
主要方法:
- 关于SIMD研究近期进展的文献综述.
- 分析分子通路,包括m6ARNA甲基化和EVs.
- 检查治疗干预措施,如自主神经调节和免疫检查点抑制剂.
主要成果:
- SIMD涉及炎症,氧化应激和代谢功能障碍之间的复杂相互作用.
- m6ARNA甲基化和EVs在调节心脏损伤方面发挥着至关重要的作用.
- 自主神经调节和免疫向策略显示出临床前的前景.
- 在解决免疫异质性和优化治疗时间方面仍然存在挑战.
结论:
- 了解SIMD复杂的病理生理学对于开发有效的治疗方法至关重要.
- 针对特定分子途径的精准医学方法提供了一个范式转变.
- 未来的研究应该专注于将机械学发现转化为功能恢复的临床应用.
相关概念视频
Myocarditis III: Medical Management
165
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
165
Myocarditis IV: Nursing Management
197
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
197
Cardiomyopathy V: Interprofessional Care
316
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
316
Myocarditis I: Introduction
347
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
347
Pericarditis III: Medical Management
290
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
290
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895


